This conclusion was supported by various lines of evidence: (i) loss of GATA2 reduced the viability of Ras-mutated NSCLCs, but not of WT NSCLCs; (ii) in KRAS-driven NSCLC mouse model, GATA2 loss strongly reduced tumor development. This evidence concerns the gene GATA2 and neoplasm.